This mechanistic sub-study aims to examine the effect of tranexamic acid (versus placebo) on intracranial bleeding and cerebral ischaemia. The protocol detailed here is for a mechanistic sub-study nested within the CRASH-3 trial. In particular, tranexamic acid may increase the risk of cerebral thrombosis and ischaemia. Although it is possible that tranexamic acid will reduce intracranial bleeding, there is also a potential for harm. The CRASH-3 trial hypothesizes that tranexamic acid will reduce intracranial haemorrhage, which will reduce the risk of death. The CRASH-3 trial is a randomised controlled trial that will examine the effect of tranexamic acid (versus placebo) on death and disability in 13,000 patients with traumatic brain injury. However, it is uncertain whether tranexamic acid is effective in traumatic brain injury.
Tranexamic acid prevents blood clots from breaking down and reduces bleeding.
0 kommentar(er)
